MPS1 Antibody

What is MPS1 and why are antibodies against it important in cell cycle research?

MPS1 is a protein kinase that serves as an upstream component of the spindle assembly checkpoint, which prevents anaphase onset until appropriate attachment and tension across kinetochores is achieved . It is essential for both centrosome duplication and the normal progression of mitosis . MPS1 antibodies are crucial research tools that enable scientists to:

• Visualize MPS1 localization at centrosomes and kinetochores

• Monitor phosphorylation status as an indicator of MPS1 activity

• Study the role of MPS1 in spindle assembly checkpoint activation

• Investigate centrosome duplication mechanisms

MPS1 has been detected at centrosomes in various human cell lines including RPE1 telomerase immortalized fibroblasts, U2OS osteosarcoma cells, normal and tumor-derived human breast cells, and HeLa cells .

What types of MPS1 antibodies are available for research applications?

Several types of MPS1 antibodies have been developed for different research applications:

• General MPS1 antibodies that recognize total MPS1 protein regardless of phosphorylation status (e.g., commercial antibodies from Invitrogen)

• Phospho-specific antibodies that recognize activation sites of MPS1, including:

  • Antibodies recognizing the T490 phosphorylation site on the T-loop

  • Antibodies recognizing the N-terminal phosphorylation sites (T33/S37)

• Antibodies generated against specific regions of MPS1, such as the affinity-purified rabbit polyclonal antibody (hMps1Ag3) generated against amino acids 400-507

These various antibodies enable researchers to study different aspects of MPS1 biology, from protein localization to activation status.

How can MPS1 antibodies be used to study spindle assembly checkpoint function?

MPS1 antibodies can be employed in several methodological approaches to study the spindle assembly checkpoint:

• Immunofluorescence microscopy: Antibodies against MPS1 can be used to visualize its localization during different stages of mitosis. This approach can be combined with anticentromere antibodies (ACA) and other checkpoint proteins like BubR1, Mad1, and Mad2 to study their co-localization and recruitment dependencies .

• Quantitative analysis of kinetochore recruitment: By normalizing pixel intensities of MPS1 to ACA signals, researchers can quantitatively assess MPS1 recruitment to kinetochores under different experimental conditions .

• Phosphorylation-specific detection: Using phospho-specific antibodies that recognize MPS1 activation sites allows researchers to monitor the activation status of MPS1 during mitotic progression and in response to spindle poisons .

• RNAi combination studies: MPS1 antibodies can be used to verify knockdown efficiency in RNAi experiments targeting MPS1 or its regulators like PP1-87B, helping to establish the relationship between MPS1 and other checkpoint components .

How can phospho-specific MPS1 antibodies be utilized to investigate kinase regulation mechanisms?

Phospho-specific MPS1 antibodies have proven invaluable for exploring the complex regulatory mechanisms controlling MPS1 activity:

• Monitoring autophosphorylation: The T490 phospho-specific antibody can be used to track MPS1 activation via autophosphorylation of its T-loop, a critical step in MPS1 activation .

• Studying phosphatase regulation: When combined with phosphatase inhibition or depletion experiments (e.g., PP1-87B RNAi), these antibodies can reveal how phosphatases like PP1 regulate MPS1 activity. For instance, depletion of PP1-87B resulted in a substantial increase in Mps1 T-loop autophosphorylation during prometaphase and on metaphase kinetochores .

• Quantitative microscopy analysis: By measuring the fluorescence intensity of phospho-MPS1 staining normalized to total kinetochore markers, researchers can quantitatively assess how different experimental manipulations affect MPS1 activation status .

• Temporal dynamics studies: Phospho-specific antibodies enable the tracking of MPS1 activation throughout different stages of mitosis, revealing when and where the kinase is active .

What methodological approaches can resolve contradictory findings about MPS1's role in centrosome duplication?

The literature contains conflicting reports regarding MPS1's role in centrosome duplication. To address these contradictions, several methodological approaches can be employed:

• Multiple antibody validation: Use multiple antibodies targeting different regions of MPS1 to confirm centrosomal localization. For example, the hMps1Ag3 antibody specifically recognizes centrosomes in various human cell types, and this specificity can be validated by preincubation with recombinant MPS1 proteins .

• Complementary genetic approaches: Combine antibody-based detection with genetic manipulations, such as:

  • Overexpression of dominant-negative MPS1 (hMps1KD)

  • siRNA-mediated knockdown of MPS1

  • Inducible expression systems for wild-type and mutant MPS1

• Cell type considerations: Test hypotheses across multiple cell types, as observed in studies that detected MPS1 at centrosomes in RPE1, U2OS, HeLa, and breast cancer cells .

• Functional readouts: Combine localization studies with functional assays for centrosome duplication, such as:

  • Centrosome reduplication assays in U2OS cells

  • Quantification of centrosome numbers after MPS1 manipulation

  • Co-localization with established centrosome markers

How can MPS1 antibodies be used to investigate the relationship between MPS1 and chromosomal instability in cancer?

MPS1 deregulation has been linked to chromosomal instability and aneuploidy in human tumors . MPS1 antibodies can facilitate this research through:

• Comparative expression analysis: Measure MPS1 levels and phosphorylation status in matched normal and tumor tissues or cell lines using validated antibodies.

• Activity correlation studies: Use phospho-specific antibodies to correlate MPS1 activation with chromosomal instability markers in patient samples.

• Inhibitor efficacy assessment: Use MPS1 antibodies to measure target engagement and pathway inhibition when testing MPS1 inhibitors like CCT271850, which has been characterized for selective MPS1 inhibition .

• Multiparametric analysis: Combine MPS1 staining with markers of chromosomal instability, spindle checkpoint components, and cell cycle regulators to develop a comprehensive understanding of MPS1's role in cancer.

Table 1: Cellular Potency of MPS1 Inhibitor CCT271850 in Various Assays

Table adapted from data in search result

What are the optimal protocols for using MPS1 antibodies in immunofluorescence microscopy?

When using MPS1 antibodies for immunofluorescence, researchers should consider these methodological aspects:

• Fixation method: Most successful protocols use paraformaldehyde fixation (typically 4%) followed by permeabilization with Triton X-100.

• Co-staining markers: Include appropriate co-staining with:

  • Anticentromere antibodies (ACA) to mark kinetochores

  • Tubulin antibodies to visualize the mitotic spindle

  • Other checkpoint proteins (Mad1, Mad2, BubR1) to study recruitment dependencies

• Quantification approach: For quantitative analysis, normalize MPS1 or phospho-MPS1 signals to ACA intensity to account for kinetochore size variations and imaging inconsistencies .

• Image acquisition: Use confocal microscopy (e.g., Zeiss LSM 710) and appropriate image analysis software (e.g., Volocity 3D) for high-resolution imaging and quantitative analysis .

• Controls: Include specificity controls such as:

  • MPS1 depletion by RNAi to confirm antibody specificity

  • Competition assays with recombinant MPS1 protein

  • Comparison of staining patterns with multiple MPS1 antibodies

How should researchers troubleshoot inconsistent results with MPS1 phospho-specific antibodies?

When encountering inconsistent results with MPS1 phospho-specific antibodies, consider these methodological solutions:

• Antibody validation: Thoroughly validate phospho-specific antibodies using:

  • Wild-type vs. phospho-mutant MPS1 constructs

  • Lambda phosphatase treatment of samples

  • MPS1 inhibitor-treated cells as negative controls

• Sample preparation optimization:

  • Test different fixation protocols (e.g., methanol vs. paraformaldehyde)

  • Optimize permeabilization conditions

  • Use phosphatase inhibitors during sample preparation

  • Consider extracting soluble proteins before fixation to enhance kinetochore-bound signal

• Signal enhancement techniques:

  • Implement tyramide signal amplification for weak signals

  • Test different antibody concentrations and incubation times

  • Consider using monoclonal secondary antibodies for reduced background

• Technical variables:

  • Control for cell cycle stage (synchronization may be necessary)

  • Account for rapid MPS1 turnover at kinetochores (reported half-life differences between prometaphase and metaphase)

  • Consider that phosphorylation is dynamic and may require specific timing for detection

What methodological considerations are important when using MPS1 antibodies in combination with genetic manipulations?

When combining MPS1 antibodies with genetic manipulations, several methodological considerations should be addressed:

• RNAi experiments:

  • Use appropriate controls to verify knockdown efficiency

  • Consider partial vs. complete depletion effects (some MPS1 functions may require lower threshold levels than others)

  • Use multiple siRNAs to rule out off-target effects

• Overexpression studies:

  • Compare wild-type, kinase-dead (D478A), and phospho-mutant versions

  • Use inducible expression systems to control expression levels

  • Consider using fluorescently tagged constructs (e.g., EGFP-Mps1) to distinguish endogenous from exogenous protein

• Rescue experiments:

  • Design siRNA-resistant constructs for rescue experiments

  • Test multiple expression levels as both too high and too low expression can give misleading results

  • Include appropriate controls (e.g., unrescued and vector-only controls)

• Site-directed mutagenesis approaches:

  • When studying specific phosphorylation sites, compare phospho-mimetic (e.g., T→D/E) and phospho-null (e.g., T→A) mutations

  • Consider multiple mutations (e.g., K231A/F234A) that affect protein-protein interactions

How can MPS1 antibodies be integrated with live-cell imaging approaches?

Integrating MPS1 antibodies with live-cell imaging presents technical challenges but offers unique insights:

• Complementary fixed and live approaches:

  • Use fixed-cell antibody staining to validate observations from live-cell experiments with fluorescently tagged MPS1

  • Compare dynamics observed with EGFP-Mps1 to endogenous protein detected by antibodies

• FRAP analysis validation:

  • Fluorescence recovery after photobleaching (FRAP) measurements with EGFP-Mps1 have revealed differences in MPS1 turnover rates between wild-type and kinase-dead versions, and between prometaphase and metaphase kinetochores

  • Validate these observations with antibody staining in fixed cells at corresponding cell cycle stages

• Correlation with cell fate:

  • Use live-cell imaging with markers like H2B-GFP and mCherry-α-Tubulin to track cell division outcomes

  • Then perform retrospective immunofluorescence with MPS1 antibodies to correlate MPS1 status with observed phenotypes

• Biosensor development:

  • Develop FRET-based biosensors for MPS1 activity that can be validated using phospho-specific antibodies

  • Correlate biosensor signals with antibody staining to establish quantitative relationships

What are the best approaches for studying MPS1 in the context of PP1-mediated regulation?

The complex regulation of MPS1 by Protein Phosphatase 1 (PP1) can be studied using these methodological approaches:

• Phosphorylation site mapping:

  • Use phospho-specific antibodies to monitor PP1-mediated dephosphorylation of MPS1 at the T-loop (T490) and other sites

  • Combine with mass spectrometry to identify additional regulatory phosphorylation sites

• PP1-binding mutants:

  • Generate and characterize MPS1 mutants that prevent PP1 binding (e.g., K231A/F234A)

  • Use antibodies to assess how preventing PP1-mediated dephosphorylation affects MPS1 localization and activity

• Spatiotemporal regulation analysis:

  • Use phospho-specific antibodies to track MPS1 activation status at different subcellular locations (kinetochores vs. cytosol)

  • Investigate how PP1 regulates MPS1 differently at aligned versus unattached kinetochores

• Combined depletion studies:

  • Analyze the effects of co-depleting PP1 regulatory subunits (e.g., Sds22/PPP1R7) and MPS1

  • Use antibodies to track changes in phosphorylation of MPS1 substrates and checkpoint activation

How might emerging antibody technologies enhance MPS1 research?

Several emerging antibody technologies and methodological innovations could significantly advance MPS1 research:

• Single-domain antibodies and nanobodies:

  • Development of camelid-derived single-domain antibodies against MPS1 could enable live-cell imaging of endogenous MPS1

  • These smaller antibody fragments might access epitopes that are sterically hindered for conventional antibodies

• Proximity labeling approaches:

  • Combining MPS1 antibodies with proximity labeling techniques (BioID, APEX) could identify novel interactors at specific subcellular locations

  • This would help map the dynamic interactome of MPS1 throughout the cell cycle

• Super-resolution microscopy:

  • Application of super-resolution techniques with highly specific MPS1 antibodies could reveal previously unresolved spatial organization at kinetochores and centrosomes

  • These approaches could help resolve the ongoing debate about MPS1's exact role in centrosome duplication

• Single-cell technologies:

  • Integration of MPS1 antibodies with single-cell proteomics and phosphoproteomics could uncover cell-to-cell variation in MPS1 activity

  • This might be particularly relevant for understanding the heterogeneous responses to MPS1 inhibitors in cancer cells